Clinical and economical impacts of guideline implementation by the pharmaceutical care unit for high cost medications in a referral teaching hospital

Table 2 Comparison of monthly consumption of discussed medications and their relative monthly costs between pre-intervention and post-intervention groups

Variable	Medication	Pre-intervention group (n = 4946)	Post-intervention group (n = 4895)	Portion of reduction	p
Number of medications used	Albumin	5636	2771	50.83%	< 0.001
	Pantoprazole	7623	3027	60.29%	< 0.001
	IVIG	562	741	- 31.85%^a	< 0.001
Cost (USD) [mean ± SD or median (IQR)]	Albumin	245,885 ± 18,616	108,689 ± 10,429	55.8%	< 0.0001
	Pantoprazole	62,399 (7769)	10,036 (1759)	83.92%	0.004
	IVIG	69,234 ± 17,182	97,565 ± 19,164	−40.9%^a	0.022

^aNegative value means that IVIG cost and number of use increased in the post-intervention phase compared to the pre-intervention period

ISSN: 1472-6963